Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Cobitolimod Enemas in Active UC
NCT05404074Phase 1Unknown
- Sponsor
- InDex Pharmaceuticals
- Start
- Nov 2021
- Primary completion
- Oct 2022
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cobitolimod in ulcerative colitis (UC), sponsored by InDex Pharmaceuticals. Primary endpoints: Maximum observed plasma concentrations at Week 6, Time to Cmax at Week 6 and 3 more. Status: unknown.
02
Drugs
cobitolimod
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05404074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05404074.